Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea's Boryung Pharma Seeking MNCs To Sell Hypertension Product Abroad

This article was originally published in The Pink Sheet Daily

Executive Summary

Boryung hopes to find alternatives like out-licensing for Kanarb in order to get around the expense of meeting EU and U.S. manufacturing standards.

You may also be interested in...

South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment

SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended

Korean Government Announces Joint Fund To Beef Up Local Pharma Industry

SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs

LG Life Science Tops R&D Investment List of Korea-Listed Pharmas

SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts